Atorvastatin 20mg
ApprovedRecruiting 0 watching 0 views this week📈 Rising
77
Development Stage
✓
Pre-clinical✓
Phase 1✓
Phase 2✓
Phase 35
ApprovedIndication / Disease
Cerebrovascular Event
Conditions
Cerebrovascular Event, Stent Stenosis, Ischemic Stroke, Hemorrhagic Stroke, Stent Thrombosis, Death, Brain, Endothelial Dysfunction
Trial Timeline
Jul 30, 2024 → Dec 31, 2027
NCT ID
NCT06308952About Atorvastatin 20mg
Atorvastatin 20mg is a approved stage product being developed by Brain Biotech for Cerebrovascular Event. The current trial status is recruiting. This product is registered under clinical trial identifier NCT06308952. Target conditions include Cerebrovascular Event, Stent Stenosis, Ischemic Stroke.
Hype Score Breakdown
Clinical
30
Activity
20
Company
2
Novelty
10
Community
12
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT06308952 | Approved | Recruiting |
Competing Products
14 competing products in Cerebrovascular Event
| Product | Company | Stage | Hype Score |
|---|---|---|---|
| YM872 (zonampanel) | Astellas Pharma | Phase 2 | 52 |
| donepezil hcl | Eisai | Phase 3 | 77 |
| Donepezil hydrochloride + Donepezil matching placebo + Donepezil hydrochloride | Eisai | Approved | 85 |
| ONO-2506 | Ono Pharmaceutical | Phase 2/3 | 65 |
| Abciximab | Eli Lilly | Phase 3 | 77 |
| atomoxetine + Stimulants | Eli Lilly | Pre-clinical | 23 |
| ticagrelor + ASA + Placebo+ASA | AstraZeneca | Approved | 85 |
| Valsartan | Novartis | Pre-clinical | 23 |
| Atorvastatin | Pfizer | Approved | 84 |
| Rivaroxaban | Bayer | Pre-clinical | 20 |
| Darolutamide (BAY1841788) + Enzalutamide | Bayer | Phase 1 | 30 |
| Botulinum toxin type A + Placebo | Ipsen | Approved | 82 |
| Autologous bone marrow mononuclear cell transplantation | Brain Biotech | Phase 1 | 25 |
| Roflumilast Oral Tablet | Brain Biotech | Phase 2 | 44 |